This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Newron Pharmaceuticals SpA
Drug Names(s): NW-1029
Description: Ralfinamide is a novel compound with potent sodium channel blocking properties. Thisinvestigational drug exerts both voltage- and use-dependent inhibitory effects on TTXr (tetrodotoxin-resistant) and TTXs (tetrodotoxin-sensitive) sodium currents, with preference for TTXr currents. These channels are thought to contribute to the abnormal spontaneous firing in dorsal root ganglion neurons associated with neuropathic pain. Ralfinamide is also selective for the MAO-B enzyme (monoamine oxidase).
Deal Structure: In September 2011, Biotie Therapies and Newron Pharmaceuticals announced that they signed an agreement for Biotie to acquire Newron. In October 2011, Biotie notified Newron of its decision to exercise its right to terminate the Merger Plan and combination agreement, without further obligations from Biotie.
Additional information available to subscribers only: